PAI Pharma Acquires Nivagen Pharmaceuticals
January 8, 2026
PAI Pharma, an Olympus Partners portfolio company, acquired Nivagen Pharmaceuticals to expand domestic aseptic sterile injectable manufacturing capacity and accelerate development of ready-to-use (RTU) injectable products for hospitals. The deal adds a newly built state-of-the-art aseptic facility in Sacramento, California, and brings a pipeline of more than 20 RTU sterile injectable products.
- Buyers
- PAI Pharma, Olympus Partners
- Targets
- Nivagen Pharmaceuticals, Inc.
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Olympus Partners Acquires PAI Pharma
February 24, 2025
Pharmaceuticals
Olympus Partners has acquired PAI Pharma, a leading U.S. developer, manufacturer and distributor of generic oral liquid medicines. The platform was previously owned by Enhanced Healthcare Partners and Bourne Partners Strategic Capital; terms were not disclosed and Monroe Capital provided senior financing for the deal.
-
Hims & Hers Acquires MedisourceRx from Nivagen Pharmaceuticals
September 12, 2024
Pharmaceuticals
Hims & Hers has acquired MedisourceRx, the FDA-registered 503B outsourcing facility and business unit of Nivagen Pharmaceuticals. Bourne Partners served as exclusive financial adviser to Nivagen; proceeds from the sale will allow Nivagen to complete a sterile injectables facility in California and advance its pipeline.
-
PAI Partners Acquires Majority Stake in Nutripure
July 25, 2024
Consumer Products
PAI Partners, through its PAI Mid-Market Fund, has agreed to acquire a majority, controlling stake in Nutripure from Ardian. The investment will support Nutripure’s product development, community growth and European expansion while founders and Bpifrance remain shareholders.
-
Pfizer Completes Acquisition of Biohaven Pharmaceutical Holding Company Ltd.
October 3, 2022
Biotechnology
Pfizer completed its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC ODT (rimegepant). The all-cash transaction is valued at approximately $11.6 billion and makes Biohaven a wholly owned subsidiary of Pfizer.
-
PAI Partners to Acquire SGD Pharma from China Jianyin Investment (JIC)
June 16, 2021
Packaging
PAI Partners has made a binding offer to acquire SGD Pharma, a global manufacturer of primary glass packaging for the pharmaceutical industry, from China Jianyin Investment Ltd. (JIC). The contemplated buyout, subject to employee consultations, Ministry of Finance of China approvals and antitrust clearance, aims to accelerate SGD Pharma’s growth through organic investment and external initiatives.
-
ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M
March 9, 2021
Pharmaceuticals
ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.